Kelly John Alexander
Chief Financial Officer
Kelly John Alexander has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Feb 19, 2026.
On the most recent filing, Kelly John Alexander is listed as Chief Financial Officer at PRECISION BIOSCIENCES INC. Inside the rolling window, Kelly John Alexander reported no open-market purchases and 3 open-market sales totaling $101K in DTIL. The largest disclosed transaction in the window is a sale of 15,213 DTIL shares on Jan 21, 2026, worth $61K.
Companies traded
Other insiders at DTIL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$101K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kelly John Alexander made?
Kelly John Alexander has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company since 2025.
Which companies does Kelly John Alexander trade?
Kelly John Alexander has filed SEC Form 4 disclosures for 1 company, including DTIL.
When was Kelly John Alexander's most recent SEC Form 4 filing?
Kelly John Alexander's most recent SEC Form 4 filing on Tracefour is dated Feb 19, 2026.
What is Kelly John Alexander's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Kelly John Alexander is listed as Chief Financial Officer.
What is Kelly John Alexander's total buy and sell value in the current window?
Inside the rolling retention window, Kelly John Alexander bought $0 and sold $101K based on SEC Form 4 filings.
What was Kelly John Alexander's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 15,213 DTIL shares on 2026-01-21, worth $61K, per SEC Form 4 filings.